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Purpose: Clopidogrel is a prodrug that requires transformation into an active me-
tabolite by cytochrome P450 (CYP) in the liver in order to irreversibly inhibit the 
P2Y12 adenosine diphosphate platelet receptor. CYP2C19 polymorphism has 
been reported to correlate with reduced antiplatelet activity of clopidogrel in coro-
nary artery disease. We assessed the association between CYP2C19 polymor-
phism and clopidogrel resistance in patients with cerebrovascular disease. Materi-
als and Methods: We retrospectively gathered data from patients who experienced 
cerebrovascular disease, received clopidogrel, and were tested for clopidogrel re-
sistance and CYP2C19 polymorphism. Clopidogrel resistance was tested by the 
VerifyNow P2Y12 system, and the CYP2C19 polymorphism was tested by the See-
plex CYP2C19 ACE Genotyping system. Clopidogrel resistance was expressed in 
P2Y12 reaction units (PRU) and percent inhibition. High PRU and low percent in-
hibition suggests clopidogrel resistance. CYP2C19 polymorphisms were expressed 
as extensive, intermediate, and poor metabolizers. Clopidogrel resistance was as-
sessed according to the subgroup of CYP2C19 polymorphism. Results: A total of 
166 patients were evaluated. The PRU values of extensive CYP2C19 metabolizers 
(195.0±84.9) were significantly lower than those of intermediate and poor metabo-
lizers (237.9±88.0, 302.2±58.9). The percent inhibition of extensive metabolizers 
(44.6±21.8) was significantly higher than that of intermediate and poor metaboliz-
ers (30.5±21.5, 14.0±13.4). Conclusion: Intermediate and poor metabolizing CY-
P2C19 polymorphism is associated with reduced clopidogrel antiplatelet activity 
in patients with cerebrovascular disease. The clinical implications of this finding 
require further investigation.
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INTRODUCTION
   
Clopidogrel is widely used for secondary prevention of ischemic cerebrovascular 
disease. However, a substantial number of patients experience cerebrovascular or 
cardiovascular attack, even with the use of clopidogrel. Several studies have report-
ed that reduced clopidogrel response ranges from 4.8-50%.1,2 The potential mecha-
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the effects of CCBs on clopidogrel’s antiplatelet activity. 
MATERIALS AND METHODS
　　　
Subjects
We retrospectively reviewed the cases of patients with cere-
brovascular disease who received clopidogrel for the preven-
tion of ischemic stroke from January 2009 to June 2010. We 
selected patients who were tested for clopidogrel resistance 
and CYP2C19 polymorphism. We required that the patients 
be given clopidogrel for at least six days before the clopido-
grel resistance test in order to be enrolled in this study. In all 
patients, CYP2C19 polymorphism testing was done after in-
formed consent was obtained according to the National Bio-
ethics Committee regulation. A total of 166 patients who had 
previously experienced cerebrovascular disease and received 
clopidogrel were enrolled. The patients had either cerebral 
infarction or intra/extracranial artery stenosis. 
Clopidogrel resistance and CYP2C19 Genotyping
All patients received 75 mg/day clopidogrel for at least six 
days before clopidogrel resistance testing. Clopidogrel resis-
tance was tested by the VerifyNow P2Y12 assay (Accumet-
rics, San Diego, CA, USA). The VerifyNow P2Y12 assay is 
a whole blood, light transmission-based optical detection 
assay that measures platelet aggregation in a cartridge con-
taining fibrinogen-coated beads. The assay was performed 
according to the manufacturer’s directions within 10 to 15 
minutes of venous sampling. The results are expressed as 
percent inhibition and PRU. Percent inhibition was calcu-
lated as [1-(PRU/baseline PRU)]×100. The PRU indicates 
the amount of ADP P2Y12 platelet receptor mediated plate-
let aggregation and is inversely related to antiplatelet func-
tion. If the PRU is high, then percent inhibition and anti-
platelet activity is decreased. 
The CYP2C19 polymorphism was tested by the Seeplex 
CYP2C19 ACE Genotyping system (Seegene, Seoul, Ko-
rea). The Seeplex CYP2C19 ACE Genotyping system is a 
simple, innovative dual priming oligonucleotide primer-
based multiplex polymerase chain reaction system having 
maximal specificity and sensitivity for detecting two single 
nucleotide polymorphisms (CYP2C19*2, CYP2C19*3 al-
lele). The results are expressed as extensive (*1/*1 allele), 
intermediate (*1/*2, *1/*3) or poor (*2/*2, *2/*3, *3/*3) 
metabolizers. 
To evaluate the correlation between CYP2C19 polymor-
nisms of such insufficient responses to clopidogrel are af-
fected by several factors, including variable absorption of 
the prodrug, clearance of the active metabolite, potential 
drug-drug interactions,3 the ability of thrombin to bypass 
complete adenosine diphosphate (ADP) inhibition,4,5 ADP 
-mediated P2Y12 platelet receptor variability, genetic poly-
morphisms of platelet receptors, and differences in platelet 
signal transduction pathways. Clopidogrel is a prodrug that 
requires transformation into an active metabolite by cyto-
chrome P450 (CYP) in the liver in order to irreversibly inhib-
it P2Y12 ADP platelet receptor. This transformation is a 
complex process, involving a number of CYP isoenzymes 
(CYP1A2, CYP2B6, CYP2C9, CYP3A4, and CYP2C19) in 
varying degrees.6 The CYP2C19 enzyme is known to have 
the most important role related to clopidogrel transforma-
tion. CYP2C19 polymorphism has been reported to corre-
late with clopidogrel resistance in patients with coronary 
angioplasty and drug-eluting stent implantation.7-10 Also, 
drugs such as calcium channel blockers (CCB), statins, and 
proton pump inhibitors which are metabolized by CYP en-
zymes, have been reported to competitively inhibit clopido-
grel transformation, resulting in decreased clopidogrel anti-
platelet activity.11-13
It is a clinical necessity to have a reliable assay to measure 
platelet function after clopidogrel therapy for monitoring and 
dose adjustment. The VerifyNow P2Y12 assay is a rapid 
platelet function cartridge-based assay designed to directly 
measure the effects of clopidogrel on the P2Y12 receptor. 
The novel VerifyNow P2Y12 assay was designed to over-
come the limitations of the conventional optical platelet ag-
gregation test.14 The results are expressed as P2Y12 reaction 
units (PRU) and percent inhibition. Although there is no con-
sented cutoff value for either PRU or percent inhibition, low 
percent inhibition and high PRU are regarded as clopidogrel 
resistance. It has been reported that percent inhibitions below 
15% and PRUs over 213 correlate with clopidogrel resis-
tance.15 Other studies have defined percent inhibition under 
20% and PRU over 240 as clopidogrel resistance.7,16 The 
VerifyNow P2Y12 assay is superior to traditional light trans-
mission aggregometry because it is fast and correlates strong-
ly with light transmission aggregometry, with an absence of 
limitations, such as weak reproducibility and operator-de-
pendency. 
In this study, we investigated the association between 
CYP2C19 polymorphism and clopidogrel resistance, as 
measured by the VerifyNow P2Y12 assay in patients with 
ischemic cerebrovascular disease. In addition, we studied 
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and laboratory findings, are shown in Table 1. The numbers 
of extensive, intermediate, and poor CYP2C19 metabolizers 
were 68 (40.9%), 74 (44.6%), and 24 (14.5%), respectively. 
There were no significant differences in the demographic, 
clinical and laboratory findings between the CYP2C19 sub-
groups. The numbers of patients with the CYP2C19 *1/*1, 
*1/*2, *1/*3, *2/*2, *2/*3, and *3/*3 genotype were 68 
(40.9%), 56 (33.7%), 18 (10.8%), 14 (8.4%), 9 (5.4%) and 1 
(0.6%), respectively. The CYP2C19 genotype frequencies 
did not deviate significantly from Hardy-Weinberg equilib-
rium (p=0.707 for CYP2C19*2, p=0.795 for CYP2C19*3). 
The results of the VerifyNow P2Y12 assay in the CY-
P2C19 subgroups are shown in Table 2. Percent inhibition 
was highest in the extensive metabolizers and decreased in 
the intermediate and poor metabolizers (44.6±21.8, 30.5± 
21.5, 14.0±13.4; p<0.001). Post hoc analysis using the Bon-
ferroni test showed significant differences between all sub-
groups. PRU increased from extensive to poor metabolizers 
(195.0±84.9, 237.9±88.0, 302.2±58.9; p<0.001). Also, post 
hoc analysis showed significant differences between the sub-
groups.
There was a tendency toward higher PRU and lower per-
cent inhibition in patients administered a CCB than in those 
without CCB administration (PRU 247.1±85.6 vs. 220.2± 
91.5, p=0.067; percent inhibition 29.1±21.1 vs. 36.4±23.8, 
p=0.051) (Table 3). In the extensive metabolizer group, pa-
tients administered a CCB had higher PRU and lower percent 
inhibition values than patients without CCB administration 
(PRU 236.6±85.2 vs. 175.1±78.1, p=0.007; percent inhibi-
tion 34.4±20.5 vs. 49.4±21.0, p=0.004).
phism and clopidogrel resistance, patients were grouped ac-
cording to their CYP2C19 genotypes. PRU and percent in-
hibition were compared between the groups. To evaluate the 
effects of dihydropyridine CCB co-administration on clopi-
dogrel resistance, the patients were divided into two groups, 
with or without CCB.
Statistical analysis
Statistical analysis was performed with PASW Statistics 18 
(IBM, Chicago, IL, USA). Continuous variables were report-
ed as mean with standard deviation and categorical variables 
were reported as frequency and percentage. The Kolmogo-
rov-Smirnov test was used to test for normal distribution. 
Since all PRU and percent inhibition values were normally 
distributed, the analysis of variance (ANOVA) test and post 
hoc analysis were used to detect differences between the CY-
P2C19 subgroups. The chi-square test and ANOVA were 
used to compare demographic variables between the CY-
P2C19 subgroups. The student’s t-test was performed to 
compare percent inhibition and PRU between the groups 
with CCB and without CCB. Deviations from Hardy-Wein-
berg equilibrium were tested by chi-square test. A two-tailed 
value of p<0.05 was considered significant.
RESULTS
 
A total of 166 patients were enrolled in this study. Patients 
had either cerebral infarction (n=142) or intra/extracranial ar-
tery stenosis (n=24). Patient demographics, as well as clinical 
Table 1. Patient Baseline Characteristics According to CYP2C19 Metabolizer Subgroup
Extensive Intermediate Poor p value
Number of patients 68 74 24
Male sex 45 (66.2) 55 (74.3) 15 (62.5) 0.425
Age 64.2±10.6 63.8±12.4 66.5±11.6 0.595
Hypertension 48 (69.8) 47 (63.2) 18 (76.2) 0.506
Diabetes Mellitus 17 (25.4) 22 (29.8) 11 (42.9) 0.417
Smoking 38 (55.6) 33 (43.9) 11 (47.6) 0.432
LDL cholesterol (mmol/L) 2.9±1.3 2.6±0.8 2.8±1.0 0.367
Calcium channel blocker use 22 (32.4) 28 (37.8)   8 (33.3) 0.778
Statin use 40 (58.8) 46 (62.2) 18 (75.0) 0.368
LDL, low density lipoprotein.
Continuous data are shown as mean±SD. Categorical data are shown as number (%).
Table 2. Clopidogrel P2Y12 Reaction Unit and Percent Inhibition of CYP2C19 Metabolizer Subgroups
Extensive Intermediate Poor p value
PRU 195.0±84.9 237.9±88.0 302.2±58.9 <0.001
Percent inhibition   44.6±21.8   30.5±21.5   14.0±13.4 <0.001
PRU, P2Y12 reaction unit.
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large enough to mask the CCB’s contribution to clopidogrel 
resistance in the intermediate and poor metabolizer groups. 
However, the small number of extensive metabolizer group 
with CCBs merit careful interpretation of the effects of CCBs 
on clopidogrel resistance. Hypertension is a major risk fac-
tor for coronary artery and cerebrovascular disease. CCBs 
and clopidogrel are commonly co-administered for second-
ary prevention. Therefore, the effects of CCBs on clopido-
grel resistance should be confirmed by a large prospective 
clinical study. 
This study is limited by the absence of clinical outcome 
measurements. We showed only the correlation of CYP2C19 
polymorphism genotyping and the VerifyNow P2Y12 assay 
in cerebrovascular disease, which has already been demon-
strated in coronary artery disease. Considering the different 
mechanisms of ischemic stroke from coronary artery dis-
ease and the high risk of coronary stent thrombosis in pre-
vious studies of clopidogrel resistance, stroke recurrence in 
ischemic stroke patient with clopidogrel resistance may 
have different results. In addition, we did not analyze CY-
P2C19*17, which is known to be an ultra-metabolizer phe-
notype. It is possible that the presence of CYP2C19*17 in 
our intermediate metabolizer group and in such cases may 
yield unexpected results on the VerifyNow P2Y12 assay. 
However, the frequency of CYP2C19*17 has been reported 
to be very low in Asian population.20 
Our results showed a good correlation between CYP2C19 
polymorphism genotyping and the VerifyNow P2Y12 assay. 
Both diagnostic methods may play complimentary roles in 
defining clopidogrel resistance in clinical practice. Further 
prospective studies to prove the effects of clopidogrel resis-
tance on clinical outcomes and the efficacy of various meth-
ods of overcoming clopidogrel resistance, such as increased 
clopidogrel dose or other antiplatelet agents that are indepen-
dent of CYP2C19 metabolism, are needed.
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DISCUSSION
   
This study showed that individuals with poor and interme-
diate CYP2C19 metabolizers exhibited significantly de-
creased clopidogrel antiplatelet activity than those with ex-
tensive metabolizers. We used the VerifyNow P2Y12 assay 
to assess the antiplatelet activity of clopidogrel, and our re-
sults were comparable with a previous study using the same 
assay in coronary artery disease patients.7,17 Although we 
did not prove that CYP2C19 polymorphism had any clini-
cal significance in stroke recurrence, previous reports have 
suggested a high risk of cardiovascular events in poor and 
intermediate CYP2C19 metabolizer groups in coronary ar-
tery disease patients.8-10 
There was also a significant difference in the PRU and 
percent inhibition values between the poor and intermediate 
metabolizers of CYP2C19. Previous studies dichotomized 
the results of CYP2C19 polymorphisms as carriers (poor 
and intermediate metabolizers) and non-carriers (extensive 
metabolizers) and analyzed differences between carriers 
and non-carriers.8,10 This method may have been used as a 
strategy to deal with the small percentage (2.6-3%) of poor 
metabolizers in their study populations. Considering the 
higher frequency of poor metabolizers in the Asian popula-
tion, as compared to the Caucasian and Black African pop-
ulations, different antiplatelet activities between intermedi-
ate and poor metabolizers should be confirmed in clinical 
outcome studies in the Asian population.18
We found a possible role of CCBs in the inhibition of 
clopidogrel antiplatelet activity. Dihydropyridine CCBs are 
known to be metabolized by hepatic CYP3A4 and to act as 
competitive inhibitors of clopidogrel metabolism via CY-
P3A4. Studies have reported clopidogrel resistance in pa-
tients treated with CCBs.11,19 Our results showed a non-sig-
nificant trend of clopidogrel resistance in patients treated 
with CCBs and when we analyzed the effects of CCBs in 
the extensive metabolizer group, CCBs were clearly related 
to clopidogrel resistance. We speculate that the effect of 
CYP2C19 polymorphism on clopidogrel resistance was 
Table 3. Clopidogrel P2Y12 Reaction Unit and Percent Inhibition in Patients with and without Calcium Channel 
Blocker Administration
Without CCB With CCB p value
Number of patients 108 58
PRU 220.2±91.5 247.1±85.6 0.067
Percent inhibition   36.4±23.8   29.1±21.1 0.051
CCB, calcium channel blocker; PRU, P2Y12 reaction unit.
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